Fig. 4
Tumorigenesis study for stereotaxic implantation of the cells in different conditions: A 1 × 104 MSCs labeled MION-Rh; B 1 × 104 CD133+ GBM cells labeled Qdots(705 nm); C 1 × 104 MSCs labeled MION-Rh added 1 × 104 CD133+ GBM cells labeled Qdots(705 nm); D implantation of 1 × 104 CD133+ GBM cells labeled Qdots (705 nm), after the establishment of the GBM (28 days), was made the infusion in caudal vein 1 × 104 MSCs (MION-Rh); the development of tumor was followed for 20 days. A1, C1, D1 MSCs labeled MION-Rh and visualized by fluorescence detection. B1, C2, D2 CD133+ GBM cells labeled Qdot 705 nm and visualized by fluorescence detection. A2, B2, C3, D3 MSCs labeled MION-Rh and CD133+ GBM cells labeled Qdot 705 nm using combined fluorescence and X-ray detection. A3, C4 IHC analysis for Prussian blue staining of the MSCs labeled with MION-Rh. B4, D4, D5 Hematoxylin and eosin staining. B5, C6, D6 IHC analysis for GFAP. C5 IHC analysis for Ki67; B6, C7, D7 IHC analysis for VEGF. Red arrow: site of stereotaxic implantation of MSCs labeled MION-Rh. Green arrow: site of stereotaxic implantation of CD133+ GBM cells labeled Qdot (705 nm).Green circle evidenced proliferation: MSCs and CD133+ GBM cells. These images are representative of all collected MSCs and GBM samples